Flipping the odds of drug development success through human genomics

Drug development depends on accurately identifying molecular targets that both play a causal role in a disease and are amenable to pharmacological action by small molecule drugs or bio-therapeutics, such as monoclonal antibodies. Errors in drug target specification contribute to the extremely high r...

Full description

Saved in:
Bibliographic Details
Published inbioRxiv
Main Authors Hingorani, Aroon Dinesh, Kuan, Valerie, Finan, Chris, Kruger, Felix A, Gaulton, Anna, Chopade, Sandesh, Sofat, Reecha, Macallister, Raymond J, Overington, John, Hemingway, Harry, Denaxas, Spiros, Prieto-Merino, David, Juan Pablo Casas
Format Paper
LanguageEnglish
Published Cold Spring Harbor Cold Spring Harbor Laboratory Press 30.07.2017
Subjects
Drug development
Monoclonal antibodies
Online AccessGet full text

Cover

More Information
Summary:Drug development depends on accurately identifying molecular targets that both play a causal role in a disease and are amenable to pharmacological action by small molecule drugs or bio-therapeutics, such as monoclonal antibodies. Errors in drug target specification contribute to the extremely high rates of drug development failure. Integrating knowledge of genes that encode druggable targets with those that influence susceptibility to common disease has the potential to radically improve the probability of drug development success.
DOI:10.1101/170142